Inside Waabi's Bold AI Bet
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
a few seconds ago
- CNBC
Stocks are celebrating inflation's demise prematurely and the big money isn't buying, says Larry McDonald
(PRO Views are exclusive to PRO subscribers, giving them insight on the news of the day direct from a real investing pro.) The stock market and retail investors are celebrating an end to inflation worries prematurely on Tuesday, and the big money is not playing along, according to Larry McDonald of "The Bear Traps Report" — whose clients are some of the biggest hedge funds on the planet. There already was something off with the way financial markets were reacting to the July CPI report with the 10-year Treasury yield going higher after the numbers, while the Dow Jones Industrial average is rallying . Big institutional money on Wall Street is siding with the bond market and believes that inside of the CPI report were the signs of a growing comeback in inflation. They are looking at what's called "supercore" inflation, which removes food and energy, but also shelter and rent costs from the headline number. When that's taken out, inflation was running at a 3.21% rate last month, much higher than the 2.7% headline annual rate that was slightly less that economists expected and sparked the equity rally. "This could be like a nice relief rally today, but under the surface, inflation is just not coming down fast enough and that's not great for bonds," said McDonald, author of " How To Listen When Markets Speak. " Supercore "is one of the most important number's the Fed looks at. ... The bond market is really focused on supercore and you can't fake that," he said. This hidden inflation that's about to rear its head is "good for hard assets, good for gold, silver, platinum, palladium, copper," said McDonald. Big hedge funds are buying anything that comes out of the ground Tuesday, along with natural gas, he said. "The cheapest part of the market right now is natural gas," McDonald added, noting its key part in powering AI data centers. The investor and strategist pointed to the First Trust Natural Gas ETF (FCG) along with Antero Resources as ways to play along with the big money. (Watch the video above for the full conversation.)
Yahoo
28 minutes ago
- Yahoo
Cardinal Health expands urology focus with $1.9bn Solaris Health deal
US drug distributor Cardinal Health has signed a $1.9bn agreement to acquire a majority stake in Solaris Health from Lee Equity Partners. The deal aims to expand the Specialty Alliance, the distributor's multi-speciality management services organisation (MSO) platform, in which Cardinal will gain a stake of around 75%. The acquisition will also create the Urology Alliance, comprising a collaborative network of urology providers within Cardinal's Specialty Alliance MSO, as well as resonate with plans to expand the delivery of urological patient care. Cardinal's Solaris buyout complements its recent acquisitions of Urology America, Potomac Urology, and Academic Urology & Urogynaecology, signalling its urologic strategy. The transaction is expected to be completed by the end of this year, pending customary closing conditions. Cardinal Health CEO Jason Hollar stated that growing the Speciality Alliance is a 'top priority' for the company, with the latest urology purchase leaving it 'well-positioned to meet the comprehensive needs of community urologists through the robust combined capabilities of the Specialty Alliance, Specialty Networks and Cardinal Health'. Research indicates there is a shortage of urologists in the US, with 62% of US counties lacking a practising urologist and just one new urologist entering the field for every ten retiring. The figures lead to challenges in the broader field, including delayed diagnoses, increased rates of advanced-stage conditions, and significant health disparities, with these particularly pronounced in rural communities. GlobalData's senior medical analyst Selena Yu foresees Cardinal's acquisition as reflecting a shift from drug distribution with a 'lower profit margin, towards higher margin speciality care in urology'. Yu said: 'MSOs help streamline backend work like billing and staffing to allow for physicians to focus on care. 'Additionally, with a large network of specialists, patients can receive care in the same region by different care specialists, which will reduce wait times and improve care continuity. Additionally, the Cardinal Health Alliance has other specialities like oncology specialists, which makes referrals more streamlined.' Cardinal's acquisition coincided with the release of its Q4 2025 financials. The company's profits per share came in at $2.08, beating the forecasted $2.03, yet profits for the quarter came in at $60.2bn, below the $60.92bn forecast, prompting a pre-market stock drop of more than 11% on 12 August. Cardinal's share price has since recovered to a drop of around 6% to $147.05 per share, down from $157.66 per share at market close on 11 August. "Cardinal Health expands urology focus with $1.9bn Solaris Health deal" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Effettua l'accesso per consultare il tuo portafoglio
Yahoo
28 minutes ago
- Yahoo
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications. The attorney general's office said in a statement that the company bribed and illegally induced medical providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound, used for weight loss and diabetes treatment. "Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Attorney General Paxton said. The lawsuit builds upon Attorney General's previous legal action to hold drug manufacturers accountable for fraud and abuse, the statement added. Last year, Paxton had sued insulin manufacturers, including Lilly and pharmacy benefit managers (PBMs), alleging that manufacturers artificially raised the prices of insulin and then paid a significant, undisclosed portion back to the PBMs for preferential treatment in return. Eli Lilly did not immediately respond to a Reuters request for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
